World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ISRCTN
Last refreshed on: 19 December 2016
Main ID:  ISRCTN63299516
Date of registration: 30/04/2015
Prospective Registration: Yes
Primary sponsor: Laboratorios procaps S.A.
Public title: Efficacy and safety comparison of a plant essential oil formulation vs traditional shampoo for Demodex ophthalmic infection treatment
Scientific title: Production and evaluation of a formulation for prevention and treatment of blepharitis and keratoconjunctivitis caused by the ectoparasite Demodex Sp
Date of first enrolment: 04/05/2015
Target sample size: 158
Recruitment status: Completed
URL:  http://isrctn.com/ISRCTN63299516
Study type:  Interventional
Study design:  Double blind interventional open randomized controlled trial (Treatment)  
Phase: 
Countries of recruitment
Colombia
Contacts
Name: Martha    Lizarazo
Address:  CLL 86 No. 50-158 080001 Barranquilla Colombia
Telephone: +5753363700
Email: marthailiz2@hotmail.com
Affiliation: 
Name: Gonzalo    Nieto
Address:  Eye Clinic Caribbean (Clínica Oftalmológica del Caribe) Calle 80 No 78B 201 080001 Barranquilla Colombia
Telephone: +573183501472
Email: gnieto@procaps.com.co
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: 1. Men and not pregnant or lactating women = 18 years of age
2. Blepharitis Acarida by Demodex sp clinical diagnosis
3. Written informed consent

Exclusion criteria: 1. Current or recent (two weeks prior) treatment against Demodex sp
2. Oral or topic steroids consumption
3. Immunosuppressive disease medical history
4. Mental illness that does not allow an assessment of symptoms
5. Any illness that eventually requires hospitalization
6. History of malignant disease
7. Hypersensitivity to any of formulation ingredients


Age minimum:
Age maximum:
Gender: Both
Health Condition(s) or Problem(s) studied
Demodex folliculorum
Infections and Infestations
Demodex folliculorum
Intervention(s)
1. Treatment administration:
The application of the magistral formula (FM) and the shampoo control treatment (ChB) will be in charge of the principal investigator. There won´t be difference according to the assigned intervention to the patient because the treatment will be masked to the ophthalmologist who applied; for this purpose the products commercial presentations and organoleptic properties will be adjusted, so that neither the patient nor the doctor could identify the treatment group.
The eyelids of the affected patients will be subjected in ophthalmologic clinic according to the modified rubbing technique. Prior to the application of treatment, gauzes impregnated with saline solution at 39 °C will be applied in closed eyes for five minutes, in order to cause dilation of the hair follicles of the eyelashes to allow greater penetration of the product being applied.
The topical local anesthetic Alcaine® 0.5% will be administered in each eye, at the rate of one drop per eye, and an eye plastic protector shall be placed in each eye, for protecting the eye during the procedure. A moistened gauze with placebo or the intervention will be used for rubbing the roots of the lashes with a rapid movement from one end to the other of the eyelid, at a constant pressure that causes the removal of deposited debris on the base of the eyelashes. Once the gauze meets debris, this one will be changed. This procedure will be repeated until no debris gauze, which usually occurs after 4 applications for each eyelid (upper and lower).
The time between changes of the gauzes is minimal, so the procedure may be considered as continuous. When there is no debris in the gauze, the procedure will be finished.
The procedure will be performed every four days using a protocol that will try to control all the stages of the parasite cycle and a total duration of 6.2 weeks
2. Associated interventions:
In both groups the recommendations of the ophthalmologist includes:
2.1. Wash sheets and pillow
Primary Outcome(s)
Demodex infestation index:
To determine the presence of mites 4 eyelashes per eye will be extracted under slit lamp with a watchmaker forceps, alternating between upper and lower eye lid. Once removed, the eyelashes will be mounted onto glass slide and observed in the CHT ® Olympus microscope with objectives 4x, 10x, 40x; the count is conducted with the objective of 4x and counted equally all stages of mite. Subsequently the parasite index mites/eyelash will be calculated by dividing the number of mites found on the total observed eyelashes. The IP will be considered positive if = 0.5. The finding of 4 – 5 demodex mites will be interpreted as an intense parasite degree. The existence of a single mite in all eyelashes won’t be interpreted as significant infection data.

In subsequent monitoring (day 7 and 21 post-treatment) only will be necessary to remove one eyelash per lid, 4 per evaluation. The growth of eyelashes is 21 days on average, a total of 20 eyelashes are used by patient.
Secondary Outcome(s)
Assessment of symptoms of blepharitis:
It will be evaluated through an 11 points analog visual scale (EVA), where zero (0) will represent the symptoms absence and ten (10) as the highest symptoms value. The instrument will be explained to the patients before its application.
Secondary ID(s)
N/A
Source(s) of Monetary Support
Laboratorios Procaps S.A
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history